Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Capital Expenditures: 2017-2025

Historic Capital Expenditures for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $863,000.

  • Crinetics Pharmaceuticals' Capital Expenditures rose 63.45% to $863,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 68.88%. This contributed to the annual value of $3.8 million for FY2024, which is 18.00% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Capital Expenditures of $863,000 as of Q3 2025, which was down 73.05% from $3.2 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Capital Expenditures high stood at $3.5 million for Q3 2023, and its period low was $18,000 during Q4 2021.
  • In the last 3 years, Crinetics Pharmaceuticals' Capital Expenditures had a median value of $955,000 in 2024 and averaged $1.3 million.
  • Data for Crinetics Pharmaceuticals' Capital Expenditures shows a peak YoY increase of 3,936.36% (in 2024) and a maximum YoY decrease of 84.91% (in 2024) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Capital Expenditures (Quarterly) stood at $18,000 in 2021, then skyrocketed by 1,422.22% to $274,000 in 2022, then surged by 241.24% to $935,000 in 2023, then grew by 10.05% to $1.0 million in 2024, then skyrocketed by 63.45% to $863,000 in 2025.
  • Its Capital Expenditures stands at $863,000 for Q3 2025, versus $3.2 million for Q2 2025 and $1.2 million for Q1 2025.